Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Clinical trial NCT05746208 · RECRUITING

Trial details

NCT number: NCT05746208
Sponsor: University of California, San Francisco
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Tumors Well-Differentiated Neuroendocrine Carcinoma High Grade Neuroendocrine Carcinoma, Any Site

Start date: 2023-07-17
Primary completion: 2028-01-31
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.